Welcome to our dedicated page for Rockwell Med SEC filings (Ticker: RMTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rockwell Medical, Inc. (Nasdaq: RMTI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Rockwell Medical files current reports on Form 8-K and periodic reports such as Form 10-Q, which together offer detailed information on its financial condition, operating performance, corporate governance, and key business developments related to its hemodialysis products for dialysis providers worldwide.
Through Rockwell Medical’s Form 8-K filings, users can review disclosures about material events, including quarterly financial results, updated corporate presentations, and changes in the composition of the board of directors or executive leadership. For example, the company has used Form 8-K to announce financial results for specific quarters, to furnish investor presentations, and to report appointments and resignations of directors and senior officers, along with related compensation and equity awards.
Quarterly reports on Form 10-Q, referenced in Rockwell Medical’s announcements, contain more extensive financial statements and notes, as well as management’s discussion of net sales, gross profit, gross margin, operating income or loss, adjusted EBITDA, and cash position. These filings also provide context on customer contracts, such as the impact of large customers transitioning to other suppliers and the extent of long-term agreements with dialysis providers.
On Stock Titan, Rockwell Medical’s SEC filings are presented with real-time updates from the EDGAR system and AI-powered summaries that explain the key points in plain language. Users can quickly understand the implications of a new 8-K or 10-Q, see how financial metrics are trending, and identify disclosures about corporate governance or compensation arrangements. This page is a resource for investors and analysts who want to examine Rockwell Medical’s official regulatory history and interpret the company’s hemodialysis-focused business through its SEC reports.
Rockwell Medical (RMTI) reported a sharp decline in sales following reduced volumes from its largest customer. Net sales were $16.1 million for the quarter (down 38% year-over-year) and $35.0 million for the six months (down 28%). Gross margin held near 16%, but the company recorded a net loss of $1.5 million for the quarter and $3.0 million year-to-date, driven largely by a $9.9 million quarterly reduction in DaVita purchases and a $14.6 million reduction for the six-month period.
Liquidity sources include $18.4 million of cash, cash equivalents and short-term investments, $21.1 million available under an ATM facility, and net working capital of $20.7 million; management believes these resources are sufficient for at least the next twelve months. The Company has an outstanding term loan with a net carrying amount of $8.6 million, current deferred consideration of $2.5 million, and completed remediation with its lender by submitting updated projections. The Company also disclosed a new multimillion-dollar supply agreement with IRC with three-year utilization commitments.
Rockwell Medical, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025, and attached that press release as Exhibit 99.1 to this Current Report on Form 8-K. The company explicitly states the information in Item 2.02 and Exhibit 99.1 is being furnished and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into Securities Act filings except by specific reference. Item 9.01 lists the furnished exhibits: Exhibit 99.1 (press release) and Exhibit 104 (Cover Page Interactive Data File in Inline XBRL). The report is signed on behalf of the registrant by Mark Strobeck, Chief Executive Officer.
Rockwell Medical, Inc. (RMTI) filed a Form 144 indicating that 6,926 common shares may be sold under Rule 144. The proposed transaction will be executed through Raymond James & Associates on or after 1 July 2025.
The shares were acquired via RSU vesting on 17 March 2024. At the indicated aggregate market value of $5,536, the filing equates to roughly 0.02 % of the company’s 34.17 million shares outstanding; therefore, the sale is immaterial to share-count dilution and likely has negligible impact on liquidity.
The seller identified in the past-sales table is Mark Strobeck, who disposed of an identical 6,926-share block on 1 April 2025 for gross proceeds of $7,263. The current notice affirms that the filer is not aware of undisclosed material adverse information and is acting in compliance with SEC Rule 144 and related insider-trading provisions.
Overall, the filing represents routine insider portfolio management rather than a signal of fundamental change.